NGNE241220P25000
- 3.10
- 0.000.00%
Neurogene Newsroom
William Blair Maintains Neurogene(NGNE.US) With Buy Rating
William Blair Reaffirms Their Buy Rating on Neurogene (NGNE)
Neurogene Files to Sell 4M Shares of Common Stock for Holders
Neurogene Inc. Sees Significant Stock Purchases by Samsara BioCapital
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Neurogene and Ventyx Biosciences Rises After Insider Buying by Executives
J.M. Smucker Posts Upbeat Earnings, Joins LexinFintech, Semtech, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
Neurogene CEO Rachel McMinn Acquires $968,999 in Stock
Insider Purchase: President and CFO of $NGNE (NGNE) Buys 24,000 Shares
H.C. Wainwright Maintains Neurogene(NGNE.US) With Buy Rating, Maintains Target Price $55
Neurogene Price Target Maintained With a $55.00/Share by HC Wainwright & Co.
Neurogene Adjusts Clinical Trial After Setback
Express News | Neurogene Shares Shares Down 5.5% After the Bell Following Announcement That Trial Participant Died, FDA Allowing It to Proceed With Trial for Rett Syndrome
Express News | Neurogene Inc - FDA Allows Neurogene to Proceed With Phase 1/2 Trial Using 1E15 Vg Dose
Express News | Neurogene Inc - Participant in Neurogene's Phase 1/2 Trial for Rett Syndrome Dies
Stifel Maintains Neurogene(NGNE.US) With Buy Rating, Maintains Target Price $46
Express News | Neurogene Inc : Stifel Cuts Target Price to $46 From $60
Stifel Maintains Neurogene(NGNE.US) With Buy Rating, Raises Target Price to $46
TD Cowen Maintains Neurogene(NGNE.US) With Buy Rating
Neurogene's Resilient Clinical Progress and Strong Financial Position Support Buy Rating